期刊文献+

GP73联合AFP及GGT-Ⅱ检测对原发性肝癌的诊断价值 被引量:5

Dignostic value of GP73 combined with AFP,GGT-Ⅱ detection on primary liver cancer
下载PDF
导出
摘要 目的探讨联合检测高尔基体糖蛋白73(GP73)、甲胎蛋白(AFP)和γ-谷氨酰转移酶同工酶Ⅱ(GGT-Ⅱ)对原发性肝癌的诊断意义。方法分别采用化学发光免疫分析法、ELISA法和聚丙烯酰胺凝胶电泳法检测105例原发性肝细胞癌、60例肝硬化、72例乙型肝炎、30例肝良性肿瘤、90例HBV携带者和50例健康体检者血清中GP73、AFP和GGT-Ⅱ含量,分析GP73联合AFP、GGT-Ⅱ检测对原发性肝癌的诊断价值。结果原发性肝癌组GP73、AFP含量及GGT-Ⅱ阳性率明显高于良性肝病及正常对照组,差异有统计学意义(P<0.05);单独检测GP73、AFP和GGT-Ⅱ对诊断原发性肝癌的特异性分别为75.2%、84.8%和89.1%,敏感性分别为79.0%、57.1%、62.9%,联合检测GP73、AFP和GGT-Ⅱ可显著提高诊断原发性肝癌的敏感性(97.1%),但特异性有所下降。结论联合检测GP73、AFP和GGT-Ⅱ作为诊断原发性肝癌的重要指标,可显著提高原发性肝癌的诊断率。 Objective To explore the diagnostic value of GP73 combined with AFP,GGT- Ⅱ detection on primary liver cancer. Methods Serum GP73, AFP, GGT- Ⅱ levels of 105 cases of primary liver cancer, 60 cases of liver cirrhosis,72 cases of hepatitis B, 30 cases of benign tumor, 90 cases of HBV carriers and 50 cases of healthy controls were detected by ELISA, chemilunescent immunoassay and SDS-PAGE. Analysed the value of GP73 combined with AFP, GGT- Ⅱ detection on primary liver cancer. Results The levels of GP73,AFP and positive rate of GGT- Ⅱ were significantly higher than benign liver disease and healthy control group,the differences were statistically significant (P〈0.05). Specificity of GP73, AFP and GGT-Ⅱ in the diagnosis of primary liver cancer was 75.2%, 84.8% and 89.1%, respectively. Sensitivity of GP73, AFP and GGT-Ⅱ in the diagnosis of primary liver cancer was 79.0% ,57.1% and 62.9% ,respectively. The joint detection GP73 ,AFP and GGT- Ⅱ could improve the sensitivity for the diagnosis of primary liver cancer, but the specificity decreased. Conclusion The combined detection of GP73 ,AFP and GGT- Ⅱ is an important index for the diagnosis of primary liver cancer,which can improve the diagnosis rate of primary liver cancer.
出处 《中国现代医药杂志》 2014年第9期23-26,共4页 Modern Medicine Journal of China
关键词 原发性肝癌GP73 AFP GGT-Ⅱ Primary liver cancer GP73 AFP GGT-Ⅱ
  • 相关文献

参考文献10

  • 1Shoreibah MG,Bloomer JR,McGuire BM ,et al. Surveillance for hepatocellular carcinoma:evidence,guidelines and utilization[J]. Am J Med Sci ,2014,347(5) :415-419.
  • 2Bruix J, Gores G J, Mazzaferro V. Hepatocellular carcinoma :clini- cal frontiers and perspectives[J]. Gut, 2014,63 (5) : 844-855.
  • 3Rasool M,Rashid S,Arooj M,et al. New possibilities in hepato- eeUular carcinoma treatment [J]. Anticancer Res, 2014,34 (4) : 1563-1571.
  • 4Zhao YJ,Ju Q,Li GC. Tumor markers for hepatocellular carcino- malJ]. Mol Clin Onco1,2013,1 (4) :593-598.
  • 5毛一雷,杨华瑜,徐海峰,桑新亭,卢欣,杨志英,张锦春,钟守先,黄洁夫,张宏冰.新的肝癌血清标记物GP73在肝癌诊断中的初步研究[J].中华医学杂志,2008,88(14):948-951. 被引量:132
  • 6杨秉辉,任正刚.原发性肝癌诊断标准[J].中华肝脏病杂志,2000,8(3):135-135. 被引量:617
  • 7病毒性肝炎防治方案[J].中华传染病杂志,2001,19(1):56-62. 被引量:1828
  • 8Huang J,Zeng Y. Current clinical uses of the biomarkers for hep- atocellular carcinoma[J]. Drug Discov Ther,2014,8(2) :98-99.
  • 9Malek NP,Sehmidt S,Huber P,et al. The diagnosis and treatment of hepatocellular carcinoma[J]. Dtseh Arztebl Int,2014,111 (7): 101-106.
  • 10Norton PA, Comunale MA, Krakover J, et al. N-linked glyeosyla- tion of the liver cancer biomarker GP73 [J]. J Cell Bioehem, 2008,104(1 ) : 136-149.

二级参考文献5

  • 1Cassandra Willyard. Researchers look for ‘sweet' method to diagnose cancer. Nat Med, 2007, 13: 1267.
  • 2Kladney RD, Bulla GA, Guo L, et al. GP73, a novel golgilocalized protein upregulated by viral infection. Gene, 2000, 249 : 53-65.
  • 3Kladney RD, Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology, 2002, 35 : 1431-1440.
  • 4Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol, 2005, 43: 1007-1012.
  • 5徐海峰,杨华瑜,张宏冰,毛一雷.改变肝癌早期诊断和治疗现状的新肝癌血清标志物[J].基础医学与临床,2008,28(1):104-108. 被引量:117

共引文献2562

同被引文献58

  • 1蔡静清.血清TPS、AFU和NSE在原发性肝癌患者化疗监测中的应用[J].中国老年学杂志,2014,34(8):2079-2080. 被引量:3
  • 2Jemal A, Bray F, Center MM, Ferlay J, Ward t, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90 [PMID: 21296855 DOI: 10.3322/ caac.20107].
  • 3Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012, 379:1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0].
  • 4Hu B, Tian X, Sun J, Meng X. Evaluation of individual and combined applications of serum biomarkers for diagnosis of hepatocellular carcinoma: a meta-analysis. Int J Mol Sci 2013, 14:23559-23580 [PMID: 24317431 DOI: 10.3390/ ijms141223559].
  • 5Shi Y, Chen J, Li L, Sun Z, Zen L, Xu S, Zhang Y, Zhang L. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat 2011, 10:287-294 [PMID: 21517136 DOI: 10.7785/ tcrt.2012.500205].
  • 6E1 Shafie MA, Fawzy AM, A1 Monem EA, Abbass S, Zakaria DM, E1 Baz S. Golgi Protein 73 (GP73) as a novel serum marker for early detection of hepatocellular carcinoma in egyptian patients. Life Sci J 2012, 9:823-830 [DOI: 10.1111/ j.1440-1746.2011.06733.x].
  • 7Zhou ZX, Xia DN, Wang CW, Lin CQ, Zhao W, Dong C. Clinical evaluation of single or joint of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma diagnosing. Chinese-German J Clin Oncol 2012, 11:650-654 [DOI: 10.1007/s10330-012-1072-z].
  • 8Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011, 155:529-536 [PMID: 22007046 DOI: 10.7326/00034819-155-8-201110180-00009].
  • 9Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, Fimmel CJ. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000, 249:53-65 [PMID: 10831838 DOI: 10.1016/S0378-1119(00)00136-0].
  • 10Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002, 35:1431-1440 [PMID: 12029628 DOI: 10.1053/ihep.2002.32525|.

引证文献5

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部